

**Evaluating the ventilatory effect of Transnasal Humidified Rapid Insufflation Ventilatory Exchange (THRIVE) in apnoeic small children with two different oxygen flow rates: a randomised controlled trial\***

T. Riva<sup>1</sup>, N. Prével<sup>2</sup>, L. Theiler<sup>3,7</sup>, R. Greif<sup>3,8</sup>, Lukas Bütikofer<sup>5</sup>, F. Ulmer<sup>6</sup>, S. Seiler<sup>1</sup>, S. Nabecker<sup>4,9</sup>

1 Consultant, 2 Staff, 3 Professor, 4 Staff, Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Switzerland.

5 Senior statistician, CTU Bern, University of Bern, Switzerland

6 Consultant, Department of Paediatrics, Section of Paediatric Critical Care, Bern University Hospital, University of Bern, Switzerland.

7 Professor, Department of Anaesthesia, Kantonsspital Aarau, Aarau, Switzerland

8 Professor, School of Medicine, Sigmund Freud University Vienna, Vienna, Austria

9 Clinical Fellow, Department of Anaesthesia and Pain Management, Sinai Health System, University of Toronto, Toronto, Canada

Correspondence to:

Thomas Riva  
Department of Anaesthesiology and Pain Medicine,  
Bern University Hospital  
University of Bern,  
Freiburgstrasse  
3010 Bern  
Switzerland  
E-Mail: [Thomas.riva@insel.ch](mailto:Thomas.riva@insel.ch)

Key words: Apnoeic oxygenation – Airway physiology – Paediatric anaesthesia - Difficult airway – HFNT

**Twitter handle:** author S. Nabecker: @sabinenabecker

**Short title:** Ventilatory effect of high-flow nasal therapy

**\*Prior presentations**

Parts of the results were presented at the WAMM 2019 in Amsterdam, The Netherlands, by Nadège Prével, 16<sup>th</sup> November 2019.

**Word count:** summary 244/250 words, Article 3468

Number of figures: 3, number of tables: 3, number of appendices: 2 tables, 1 figure

## Summary

Transnasal Humidified Rapid Insufflation Ventilatory Exchange (THRIVE) prolongs safe apnoeic oxygenation time in children. In adults, THRIVE is reported to have a ventilatory effect with PaCO<sub>2</sub>-levels increasing less rapidly than without THRIVE. This ventilatory effect has yet to be reproduced in children. In this non-inferiority study, we tested the hypothesis that children weighing 10-15 kg exhibit no difference in CO<sub>2</sub>-clearance when comparing two different high flow nasal therapy (HFNT) flow rates during a 10-min apnoea period.

Following standardised anaesthesia induction including neuromuscular blockade, patients were randomised to two groups: HFNT of 100% oxygen at 2 or 4 l.kg<sup>-1</sup>.min<sup>-1</sup>. Airway patency was ensured by continuous jaw thrust.

The study intervention was terminated for safety reasons when either SpO<sub>2</sub> values dropped < 95%, or transcutaneous CO<sub>2</sub> (tcCO<sub>2</sub>) levels rose > 9.3 kPa, or near-infrared spectroscopy values dropped > 20% from their baseline values, or after an apnoeic period of 10 minutes.

Fifteen patients were included in each group. In the 2 l.kg<sup>-1</sup>.min<sup>-1</sup> group the mean tcCO<sub>2</sub>-increase was 0.46 (0.11) kPa.min<sup>-1</sup>, in the 4 l.kg<sup>-1</sup>.min<sup>-1</sup> group it was 0.46 (0.12) kPa.min<sup>-1</sup>. The upper limit of a one-sided 95% CI for the difference between groups was 0.07 kPa.min<sup>-1</sup>, lower than the predefined non-inferiority margin of 0.147 kPa.min<sup>-1</sup> (p=0.001). The lower flow rate of 2 l.kg<sup>-1</sup>.min<sup>-1</sup> was non-inferior to 4 l.kg<sup>-1</sup>.min<sup>-1</sup> relative to the tcCO<sub>2</sub>-increase.

In conclusion, an additional ventilatory effect of either 2 or 4 l.kg<sup>-1</sup>.min<sup>-1</sup> HFNT in apnoeic children weighing 10-15 kg appears to be absent.

## **Introduction**

High-flow nasal therapy (HFNT) is the administration of heated, humidified and blended air/oxygen via nasal cannula at rates of at least  $2 \text{ l.kg}^{-1}.\text{min}^{-1}$  [1]. HFNT can be used in spontaneously breathing and apnoeic patients in a variety of clinical settings and age groups. In preterm infants, it is used for treatment of respiratory distress of different aetiologies [2] and for respiratory support after extubation [3]. In infants, it is used for the treatment of bronchiolitis [4] and other respiratory illnesses. Its use in adults focuses on hypoxaemic respiratory failure in intensive care unit patients [5] and on improving oxygenation during intubation [6,7], preoxygenation [7,8], awake fibre-optic intubation in adults with difficult airways [9] and morbidly obese patients [10]; or tubeless surgery [11]. In paediatric anaesthesia HFNT has been used during paediatric airway surgery [12-14] and during induction of anaesthesia for healthy children [15]. The application of HFNT in apnoeic adults and children is called transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) and was first described in 2015 in a case series of 25 patients [16]. HFNT prolongs safe apnoeic oxygenation period in adults and children undergoing hypopharyngeal or laryngotracheal surgery [12,16] and during intubation in healthy children [17]. Apart from extending the safe apnoeic oxygenation period, THRIVE is believed to have a ventilatory effect in adults, because of the slower than expected increase in  $\text{CO}_2$  [16,18]. The concept that THRIVE facilitates  $\text{CO}_2$ -clearance during apnoeic oxygenation is also supported by recent simulation [19] and model studies [20]. Both Patel et al. [16] and Gustafsson et al. [18] compared their data to data from studies from two studies from 1959 and 1961 [21,22]. From our own group, Riva et al. [15] and Humphrey et al. [17], showed that the ventilatory effect of THRIVE found in adults could not be reproduced in children between 1 and 10 years of age. We directly compared different flow rates in relation to  $\text{CO}_2$  clearance and postulated that there is no ventilatory benefit in terms of  $\text{CO}_2$  clearance when comparing low flow rates of  $0.2 \text{ l.kg}^{-1}.\text{min}^{-1}$  and high flow rates of  $2 \text{ l.kg}^{-1}.\text{min}^{-1}$  [15]. After publication, these results were challenged by comments that the HFNT flow rate of  $2 \text{ l.kg}^{-1}.\text{min}^{-1}$  might have been too low to demonstrate  $\text{CO}_2$ -clearance in children and that the chosen flow rate was not equivalent to the  $70 \text{ l.min}^{-1}$  used in adult patients [23,24]. We therefore decided to conduct a non-

inferiority study, designed to systematically investigate CO<sub>2</sub> clearance in healthy children weighing 10-15 kg during apnoea at flow rates of 2 and 4 l.kg<sup>-1</sup>.min<sup>-1</sup> in order to determine whether ventilatory effect in children occurs.

## **Methods**

With approval from the Cantonal Ethics Committee of Bern (reference number KEK-BE: 2018-01848, 12<sup>th</sup> December 2018) and after registering with ClinicalTrials.gov (NCT03812354), we obtained written informed consent from the parents or legal guardians of the targeted patients prior to study enrolment.

This prospective, single centre, single-blinded, randomised controlled non-inferiority trial was conducted at the Bern University Hospital in Bern, Switzerland between March 2019 and February 2020. Inclusion criteria included paediatric patients undergoing elective surgery requiring general anaesthesia including tracheal intubation, with an ASA physical status of 1 or 2, weighing 10-15kg. Exclusion criteria included known or suspected difficult intubation, known or anticipated difficult bag-mask ventilation, oxygen dependency, congenital heart or lung disease, obesity (BMI >30 kg.m<sup>-2</sup>), contraindication for neuromuscular blocking agents, upper airway obstruction, high risk of aspiration (requiring rapid sequence induction), and parents not speaking or understanding German. Eligible children were identified from theatre lists and recruited during the mandatory preadmission anaesthesia visit.

Patients were randomised using computer-generated randomization ([www.randomization.com](http://www.randomization.com)) and sealed opaque envelopes. Envelopes were opened after induction of anaesthesia and once successful facemask ventilation was confirmed. Blinding of study personnel was not feasible, but patients and parents were blinded to group allocation.

All patients were premedicated with 0.5 mg.kg<sup>-1</sup> midazolam (oral or rectal) or 2 mcg.kg<sup>-1</sup> nasal dexmedetomidine. Before induction of anaesthesia, patient characteristics (Table 1) and vital signs were recorded [pulse oximetry, ECG, non-invasive blood pressure, end-tidal CO<sub>2</sub>, transcutaneous CO<sub>2</sub> (tcCO<sub>2</sub>) and transcutaneous O<sub>2</sub> (Tosca™, Radiometer, Neuilly-Plaisance, France), Near-infrared spectroscopy - NIRS (Nonin Medical inc., Plymouth, MN, USA)]. NIRS was used both as an indirect parameter to investigate possible vasodilation of the cerebral arteries as a result of hypercapnia and as a safety parameter only during the study. Since we wanted to make sure that the apnoeic

oxygenation period did not cause hypoxia, we used NIRS for this purpose as well. A 20% reduction in the value of brain saturation is the standard value for detecting possible hypoxia. Intravenous access was established. In the event that venous access was difficult to obtain, patients were induced with inhaled sevoflurane followed by placement of an intravenous cannula. Intravenous induction was performed with propofol 2-4 mg.kg<sup>-1</sup>, fentanyl 2 mcg.kg<sup>-1</sup> or alfentanil 20 mcg.kg<sup>-1</sup>. General anaesthesia was maintained using propofol at a continuous infusion rate of 10 mg.kg<sup>-1</sup>.h<sup>-1</sup> or by administering repeatedly fractionated 2 mg.kg<sup>-1</sup> propofol as necessary. For safety reasons exclusively during the study, anaesthetic depth was assessed using processed frontal EEG (Narcotrend™, Hannover, Germany), maintaining values between 40 and 60. After induction of anaesthesia, all patients received 0.5-1 mg.kg<sup>-1</sup> of rocuronium. Neuromuscular blockade was assessed using train-of-four (TOF) monitoring (TOF-Watch, Organon Ltd, Dublin, Ireland). A TOF value of zero was verified upon the onset of apnoea and repeatedly checked throughout the entire procedure.

After induction of anaesthesia, bag-mask ventilation with 100% oxygen and flow rates of 6-8 l.min<sup>-1</sup> was performed until the following values were reached: (i) TOF = 0; (ii) expired oxygen concentration over 90%; (iii) tcCO<sub>2</sub> 4-5.3 kPa; and (iv) Narcotrend values between 40-60. Upon reaching these values, bag-mask ventilation was discontinued and defined as the beginning of the apnoea period. Oxygen administration was performed according to randomization to one of two treatment groups; HFNT with flow rate of 2.0 l.kg<sup>-1</sup>.min<sup>-1</sup> or HFNT with flow rate of 4.0 l.kg<sup>-1</sup>.min<sup>-1</sup>.

Both groups received 100% oxygen; fresh gas was delivered using the Optiflow™ system (Fisher&Paykel, Auckland, New Zealand), which was connected to the adult nasal cannula size small and RT202 tubing system. Size 'small' was used to ensure patency, so that the cannula occluded no more than 50% of the nostrils. Continuous jaw thrust was used and the insertion of an oropharyngeal airway (Guedel airway; Intersurgical®, Wokingham, UK) ensured airway patency of the oropharyngeal cavity in both groups.

Apnoea period was measured from the cessation of bag- mask ventilation until one of four predefined termination criteria was reached: (i) SpO<sub>2</sub> decreased below 95%; (ii) tcCO<sub>2</sub> increase above 9.3 kPa; (iii) drop of NIRS value of more than 20% from baseline; or (iv) completion of 10 min apnoea period. Once one of these criteria was met, apnoea was terminated immediately, and bag-mask ventilation was resumed which concluded the study observation. Subsequent airway management and anaesthesia were performed according to the attending anaesthesiologist.

During the apnoea period, tcCO<sub>2</sub> (kPa) and O<sub>2</sub> concentrations were recorded every second. Chest ultrasound was performed at the end of the intervention to rule out the presence of a pneumothorax (Sonosite M-Turbo; FUJIFILM SonoSite Inc, Bothell, WA, USA). Parents were queried if they had observed postoperative side effects including nausea and vomiting, stridor, coughing, laryngospasm, bronchospasm, pain or other complications such as delirium, prior to their children leaving the postanesthesia care unit.

The primary outcome parameter was the mean tcCO<sub>2</sub> increase in kPa.min<sup>-1</sup> during the apnoea period. Secondary outcome parameters included changes in tcO<sub>2</sub> in kPa.min<sup>-1</sup> and changes in brain oxygenation measured by NIRS during the apnoea period as well as the occurrence of unexpected side effects.

We used a non-inferiority design for the primary outcome, i.e. we tested whether the difference of the mean increase in tcCO<sub>2</sub> between the groups (2 l.kg<sup>-1</sup>.min<sup>-1</sup> minus 4 l.kg<sup>-1</sup>.min<sup>-1</sup>) was less than the predefined non-inferiority margin of 0.147 kPa.min<sup>-1</sup>. The margin was based on a 25% difference from the value we obtained in our previous study [15] and value extrapolated from adults studies [16,18]. Assuming a standard deviation of 0.147 kPa.min<sup>-1</sup> and a one-sided alpha of 0.05, a total of 26 patients (13 per group) were needed to detect non-inferiority with a power of 80% using a two-sample Student's t-test. To compensate for missing data and drop-outs, we planned to include fifteen patients per group.

Continuous variables are presented as mean and standard deviation (SD), or median and interquartile range (IQR). Categorical variables are presented as number (n) and percentage (%) of patients. The primary outcome (change in  $\text{tcCO}_2$  over apnoea period) was analysed for non-inferiority using a one-sided 95% confidence interval (CI) for the mean difference of lower ( $2 \text{ l.kg}^{-1}.\text{min}^{-1}$ ) minus higher ( $4 \text{ l.kg}^{-1}.\text{min}^{-1}$ ) flow. If the upper limit of the one-sided 95% CI was lower than the predefined non-inferiority margin of  $0.147 \text{ kPa}.\text{min}^{-1}$ , non-inferiority was assumed. Based on the margin, a p-value for non-inferiority was calculated. A p-value of  $<0.05$  was considered as statistically significant.

Continuous secondary outcomes were compared between groups using Student's t-tests. Effects are reported as mean difference with conventional two-sided 95% CIs. The primary analysis was based on patients with non-missing observations for a specific outcome.

We conducted four sensitivity analyses to test the robustness of our results. In a first sensitivity analysis, we included values at the start of the apnoea period (baseline) for the analysis of change scores (for  $\text{tcCO}_2$ ,  $\text{tcO}_2$ , NIRS) using a linear regression with group and baseline as covariates.

In a second sensitivity analysis, we used to complete intention-to-treat set (i.e. all 34 randomized patients), based in multiple imputations. Missing data were multiply imputed using demographic data (sex, age, weight, height), procedural characteristics (ASA, premedication, pre-operative heart rate, inhalation induction, use of propofol, dosage of rocuronium, fentanyl and alfentanil, expired oxygen concentration,  $\text{tcCO}_2$ ,  $\text{tcO}_2$ , NIRS and Narcotrend values at the end of mask ventilation), outcomes (change in  $\text{tcCO}_2$ ,  $\text{tcO}_2$ , NIRS and Narcotrend values), and the treatment group. Fifty imputations were calculated using chained equations, and predictive mean matching for continuous and logistic regression for binary outcomes. Outcomes were analysed in each dataset and combined using Rubin's rule.

In a third sensitivity analysis,  $\text{tcCO}_2$  and  $\text{tcO}_2$  values measured repeatedly over time were analysed using linear mixed-effects regression models with a random intercept and slope for each patient. Models were estimated with restricted maximum likelihood (REML) and 95% CI and p-values were calculated based on Satterthwaite's approximation for the degrees of freedom.



In a fourth sensitivity analysis, we excluded two patients in each group that were suspected to have been breathing during the analysis based on the trajectories.

For the analysis of further post-interventional characteristics continuous outcomes were compared using the Mann-Whitney-Wilcoxon test, categorical variables using Fisher's exact test. All analyses were done in Stata (StataCorp, LLC, College Station, TX, USA) version 16.0; plots were done in R version 3.6.2.

## **Results**

Thirty-four children were included in the study. Patient characteristics are summarised in Table 1. Four patients did not complete the procedure according to protocol: One in the 2 l.kg<sup>-1</sup>.min<sup>-1</sup> group and 3 in the 4 l.kg<sup>-1</sup>.min<sup>-1</sup> group. These patients had a TOF > 0 in the middle of the procedure and showed diaphragmatic respiratory movements despite having received the correct dose of rocuronium. The main analysis was based on the remaining 30 patients (see Figure 1 = Consort Flow Diagram). The median [IQR] flow in the 2 l.kg<sup>-1</sup> min<sup>-1</sup>-group was 24 [21, 28] l.min<sup>-1</sup> and 52 [42, 52] l.min<sup>-1</sup> in the 4 l.kg<sup>-1</sup>.min<sup>-1</sup>-group.

The comparison of the tcCO<sub>2</sub> at the beginning and end of the apnoea period with a flow of 2, respectively 4 l.kg<sup>-1</sup>.min<sup>-1</sup> as well as the tcCO<sub>2</sub> trajectories over time are shown in Figure 2. The fitted trajectories are outlined in Figure 3.

The overall mean (SD) rate of tcCO<sub>2</sub> increase was 0.46 (0.11) kPa.min<sup>-1</sup> for a flow of 2 l.kg<sup>-1</sup>.min<sup>-1</sup> and 0.46 (0.12) kPa.min<sup>-1</sup> for a flow of 4 l.kg<sup>-1</sup> min<sup>-1</sup>. The upper limit of a one-sided 95% CI for the mean difference (2 l.kg<sup>-1</sup>.min<sup>-1</sup> minus 4 l.kg<sup>-1</sup>.min<sup>-1</sup>) was 0.07 kPa.min<sup>-1</sup>, i.e. lower than the predefined non-inferiority margin of 0.147 kPa.min<sup>-1</sup> (Supplementary Table S1). The p-value for non-inferiority was <0.001. We can therefore assume non-inferiority at a flow of 2 l.kg<sup>-1</sup>.min<sup>-1</sup> compared to 4 l.kg<sup>-1</sup>.min<sup>-1</sup>.

Sensitivity analyses with baseline values, multiply imputed data and measurements over time confirmed this result with upper limits of the one-sided 95% of 0.07, 0.07 and 0.07, respectively, and p-values for non-inferiority of <0.001, <0.001 and 0.001, respectively (Supplementary Tables S1 and S2).

Assuming latency of the tcCO<sub>2</sub> measurements attributed to the TCM 5 device, we decided to analyse the curves excluding the first five minutes. Non-inferiority was again confirmed with an upper limit of the 95% CI of 0.08 kPa.min<sup>-1</sup> and a p-value for non-inferiority of 0.005 (Figure 3B, Supplementary Table S2).

During the apnoea period the NIRS increased by a mean (SD) of 0.27 (0.48)  $\%.\text{min}^{-1}$  (95% CI 0.01 to 0.54;  $p=0.044$ ) in the 2  $\text{l}.\text{kg}^{-1}.\text{min}^{-1}$ -group and by a mean (SD) of 0.51 (0.33)  $\%.\text{min}^{-1}$  (95%CI 0.33 to 0.69;  $p<0.001$ ) in the 4  $\text{l}.\text{kg}^{-1}.\text{min}^{-1}$  group (Table 3).

Ten patients reached the termination criterion of  $\text{tcCO}_2$  exceeding 9.3 kPa; four in the 2  $\text{l}.\text{kg}^{-1}.\text{min}^{-1}$  group and 6 in the 4  $\text{l}.\text{kg}^{-1}.\text{min}^{-1}$  group (Table 2). Desaturation ( $\text{SpO}_2$  decrease to less than 95%) occurred in 2 patients, one in each group. The remaining 18 patients completed the predefined 10 min apnoea period without incident. In the event that a termination criterion was met, bag-mask ventilation was resumed immediately. All patients had a  $\text{SpO}_2$  of greater than 92 % before the airway was secured. The two patients that desaturated below 95% recovered swiftly with bag-mask ventilation and regained saturations  $> 95\%$  within 30 seconds. No complications or desaturations were observed while the airway was being secured. No pneumothorax was identified with ultrasound imaging in any of the patients. None of the patients exhibited serious adverse events during post-op monitoring in the recovery area. One patient experienced a brief phase of postoperative delirium, which was treated successfully with propofol 1  $\text{mg}.\text{kg}^{-1}$ .

## **Discussion**

This randomised controlled non-inferiority trial demonstrates that the rate of CO<sub>2</sub>-increase with a flow rate of 2 l.kg<sup>-1</sup>.min<sup>-1</sup> is non-inferior to the rate of CO<sub>2</sub>-increase with a flow rate of 4 l.kg<sup>-1</sup>.min<sup>-1</sup> during apnoeic oxygenation when using HFNT in children weighing 10-15 kg. Higher flow rates of up to 4 l.kg<sup>-1</sup>.min<sup>-1</sup> did not enhance CO<sub>2</sub>-clearance during apnoeic oxygenation.

Preceding the introduction of HFNT to anaesthesia, the limiting factor of apnoeic oxygenation was the accumulation of CO<sub>2</sub>, causing respiratory acidosis and cardiovascular complications due to hypercapnia [21,25]. In 2015, Patel and Nouraei reported improved CO<sub>2</sub> elimination using the THRIVE-technique with an increase of CO<sub>2</sub> of only 0.15 kPa.min<sup>-1</sup>, compared to the previously published increase of CO<sub>2</sub> of 0.4 and 1.1 kPa.min<sup>-1</sup> in adults prior to the introduction of HFNT. Since then, data showing improved THRIVE-mediated CO<sub>2</sub> elimination have been reproduced for adults [18,26]. However, all studies in adults compared their results to historical data rather than to data acquired from a concurring randomised controlled trial. We therefore cannot be certain if the ventilatory effect and the enhanced CO<sub>2</sub> clearance should be attributed to the HFNT technique itself, or possibly to other factors e.g. micro-movements of the diaphragm triggered by hypercapnia, or that CO<sub>2</sub> clearance might be independent from nasal flow.

To date, three paediatric clinical studies report on the rate of tcCO<sub>2</sub> increase during apnoeic oxygenation using HFNT. In 2018 Riva et al., reported a median CO<sub>2</sub> rise of 0.51 kPa.min<sup>-1</sup> (range, 0.2–0.79 kPa.min<sup>-1</sup>) in children undergoing tubeless airway surgery with CO<sub>2</sub> accumulation representing the limiting factor of apnoeic oxygenation [12]. In 2017, a randomised controlled trial by Humphrey et al. [17] found no difference in CO<sub>2</sub> clearance between THRIVE and a control group without THRIVE (rate of CO<sub>2</sub> increase of 0.32 (0.03-0.52) kPa.min<sup>-1</sup> for both groups). The absence of enhanced CO<sub>2</sub> elimination was confirmed by Riva et al. [15] in 2018 in a randomised controlled trial which reported a rate of CO<sub>2</sub> increase of 0.57 (0.51-0.63) kPa.min<sup>-1</sup> in the group with a 0.2 l.kg<sup>-1</sup>.min<sup>-1</sup> flow and one of 0.55 (0.42-0.61) kPa.min<sup>-1</sup> in the group with a flow of 2 l.kg<sup>-1</sup>.min<sup>-1</sup>. The different CO<sub>2</sub> increase rates between the studies of Humphrey et al. [17] and Riva et al. [15] may appear surprising at first, but

should be put into context. Humphreys et al. included patients up to 10 years of age, whereas Riva et al. included children weighing only 10-15 kg. Older children have lower metabolic rates than infants and small children; a fact that might explain the higher rate of CO<sub>2</sub> increase observed in our study. The rate of CO<sub>2</sub> increase reported by Riva et al. investigating children undergoing airway surgery [12] is similar to the one found in the current study. The relative differences in the CO<sub>2</sub> increase between the first THRIVE study by Riva et al. [15] and this current study are puzzling. Both studies were conducted in the same setting but used a different tcCO<sub>2</sub> measuring device (Radiometer TCM 4 vs. Radiometer TCM 5, ToscaTM, Radiometer, Neuilly-Plaisance, France). The relative difference in tcCO<sub>2</sub> sensitivity of the TCM 4 compared to the TCM 5 could provide an explanation for the measured differences in the two studies.

While analysing the individual curves in the present study, the suspicion arose that two children in each group may have started to breathe during the apnoea phase despite the TOF remaining zero throughout the procedure. There was no clinical sign suggesting diaphragmatic movement. For this reason, their data were not excluded from the main statistical analysis. We did however decide to perform a sensitivity analysis that excluded these 4 cases. It showed that the rate of CO<sub>2</sub> increase was more closely aligned with the previously published rate of CO<sub>2</sub> increase (Table 3, Supplementary Table S1 and Supplementary Figure S3). The data of the current study confirm that an additional ventilatory effect of HFNT is absent in children weighing 10-15 kg even with higher flow rates of up to 4 l.kg<sup>-1</sup>.min<sup>-1</sup>. They also supplement and support the results of previous studies that failed to show a ventilatory effect at flow rates of up to 2 l.kg<sup>-1</sup>.min<sup>-1</sup> [15,17].

Apnoeic oxygenation occurs as oxygen passes through the upper airways to reach the alveoli. The diffusion gradient generated by the difference in alveolar oxygen extraction and carbon dioxide replacement results in subatmospheric alveolar pressures and triggers a subsequent ventilatory mass flow from the unobstructed upper airways in the direction of the alveoli [27]. This flow is thought to be supported by a cascade vortex flow, which may enhance CO<sub>2</sub> clearance as simulated by Laviola et al. [19]. The absence of pharyngeal pressure variations while the mouth is open [28] in conjunction

with the distinctive properties of the paediatric anatomy and physiology (smaller airways and a higher metabolic rate) may be responsible for the absence of significant CO<sub>2</sub>-clearance in apnoeic children subjected to HFNT. Theories attempting to explain how HFNT achieves ventilatory effect in anaesthetised and paralysed apnoeic children include dead space gas mixing, cardiogenic oscillations, and pharyngeal pressure variations. A recently published study by our research group challenged the mechanism of positive airway pressure generation as an important physiological mechanism of HFNT in adults [28]. Bidirectional air movement of around 10 mL to 30 mL per heartbeat [29,30] found in adults is caused by cardiac oscillations and might be responsible for small amounts of gas transportation. The volume of the air movement in small children (10-15 kg) is much smaller; sufficient to support oxygenation but not enough to exert an additional measurable ventilatory effect to contribute to CO<sub>2</sub> clearance. Despite the absence of a ventilatory effect, HFNT can effectively prolong the apnoea oxygenation period while preserving the integrity and function of the respiratory mucosa [31,32]. The values of NIRS during the apnoea period showed a gradual increase in brain saturation possibly caused by the hypercapnia-induced cerebral vasodilation and subsequent increase in cerebral blood flow [33].

Limitations of our study are its single-centre study design, the relatively short apnoea period of 10 minutes, the exclusion of severely ill children and the absence of blood gas analysis, which was not ethically justifiable for mere study purposes. For safety reasons, we decided to limit the apnoea period to 10 minutes and not allow tcCO<sub>2</sub> values to exceed 9.3 kPa in order to limit the effects of hypercapnia, such as acidosis, pulmonary arterial vasoconstriction, and hyperkalaemia. Similarly, we were not able to determine the influence of high flow oxygenation on altered pulmonary physiology, as severely ill children were excluded.

In conclusion, this study shows the rate of CO<sub>2</sub> increase in children undergoing general anaesthesia during apnoeic oxygenation with HFNT with flow rates of 2 l.kg<sup>-1</sup>.min<sup>-1</sup> is non-inferior to 4 l.kg<sup>-1</sup>.min<sup>-1</sup> over a 10 min apnoea period. The purported ventilatory effect of THRIVE appears to be absent in

apnoeic children and therefore represents a misnomer for this age group. The use of the acronym THRIVE should be abandoned in favour of high-flow nasal therapy - at least in children.

### **Authors' contributions**

Study design: TR, NP, FU, RG, SN

Manuscript draft: TR, NP, FU, SN

Patient recruitment, conduct of the study, data analysis and interpretation: TR, NP, LT, RG, FU

Data controlling, monitoring: SN

Statistical analysis: LB

English proofing: FU (is a native English speaker)

Finalizing the manuscript: TR, LT, RG, NP, FU, SN

### **Acknowledgement**

We wish to thank Maren Loosli, anaesthesia study nurse for her help in conducting the study and the fondation latine des voies aériennes (FLAVA-Foundation, c/o BH 10-315, Rue du Bugnon, CHUV, CH - 1011 Lausanne) for the financial support.

### **Declaration of conflict of interest**

The authors declare no competing interests.

### **Funding**


This study was financed by a departmental research grant of the Department of Anaesthesiology and Pain Medicine, University Hospital of Bern, Bern, Switzerland and by a grant of the FLAVA-Foundation (c/o BH 10-315, Rue du Bugnon, CHUV, CH - 1011 Lausanne) assigned to Thomas Riva. Optiflow nasal cannulas were donated by Fisher&Paykel (Auckland, New Zealand).

### **Electronic Appendix**

Supplementary tables and results are available at the journal's web page




**Figure 1: Consort Flow Diagram**




**Figure 2**

Measurements of transcutaneous CO<sub>2</sub> (tcCO<sub>2</sub>, kPa) over time for flows of (A) 2 l.kg<sup>-1</sup>.min<sup>-1</sup> and (B) 4 l.kg<sup>-1</sup>.min<sup>-1</sup>.



**Figure 3**

Fitted trajectories of transcutaneous CO<sub>2</sub> (tcCO<sub>2</sub> in kPa) with 95% confidence bands using (A) all data or (B) data measurements after five minutes. The dashed line represents interpolated time points.



**Table 1**

Patient characteristics. Values are number and proportion of patients, mean with standard deviation (SD) or median with interquartile range (IQR).

	Total (N = 34)	2 l kg <sup>-1</sup> min <sup>-1</sup> (N = 16)	4 l kg <sup>-1</sup> min <sup>-1</sup> (N = 18)
Female - n (%)	13 (38)	6 (38)	7 (39)
Age, years			
mean (SD)	2.2 (1.1)	2.2 (1.2)	2.1 (1.0)
median [IQR]	1.8 [1.3, 2.7]	1.9 [1.3, 2.8]	1.8 [1.4, 2.5]
Weight, kg			
mean (SD)	12 (1.7)	12 (1.8)	12 (1.5)
median [IQR]	12 [11, 13]	11 [10, 14]	12 [11, 13]
Height, cm			
mean (SD)	85 (11)	87 (10)	84 (12)
median [IQR]	84 [80, 92]	85 [79, 95]	83 [80, 91]
missing - n (%)	1 (3)	0 (0)	1 (6)
ASA - n (%)			
1	24 (71)	10 (63)	14 (78)
2	10 (29)	6 (38)	4 (22)
Premedication received - n (%)			
Dexmedetomidine	1 (2.9)	0 (0)	1 (5.5)
Midazolam	30 (88)	14 (88)	16 (89)
None	3 (8.8)	2 (13)	1 (5.5)
Specialty of surgery – n (%)			
Visceral surgery	10 (29.4)	5 (31.3)	5 (27.8)
Urology	13 (38.2)	8 (50)	5 (27.8)
Orthopedics	1 (2.9)	0 (0)	1 (5.6)
General surgery	8 (23.5)	2 (12.5)	6 (33.3)
ENT/Ophthalmology	2 (5.8)	1 (6.3)	1 (5.6)

**Table 2**

Interventional parameters. Values are number (proportion) or median with interquartile range (IQR).

	2 l.kg <sup>-1</sup> .min <sup>-1</sup> (n= 15) median [IQR] or n (%)	4 l.kg <sup>-1</sup> .min <sup>-1</sup> (n = 15) median [IQR] or n (%)	P-value
Change in SpO <sub>2</sub> during apnoea period, kPa.min <sup>-1</sup>	0 [-0.02, 0]	0 [0, 0]	0.27
Rate of flow nasally applied, l.min <sup>-1</sup>	24 [21, 28]	52 [42, 52]	<0.001
Time of intervention, min	10 [8.3, 10]	10 [9.2, 10]	0.82
Pneumothorax	0 (0%)	0 (0%)	
Study termination criteria reached	5 (33%)	7 (47%)	0.71
SpO <sub>2</sub> drops below 95%	1 (6.7%)	1 (6.7%)	1.00
Transcutaneous CO <sub>2</sub> rises above 9.3 kPa	4 (27%)	6 (40%)	0.70

**Table 3**

Primary and sensitivity analyses of the secondary outcomes change in NIRS (%.min<sup>-1</sup>) and transcutaneous O<sub>2</sub> (tcO<sub>2</sub> in kPa.min<sup>-1</sup>) over apnoea period. Values for each group are mean (SD). The mean difference between groups is presented with a 95% confidence interval (CI).

	2 l.kg <sup>-1</sup> .min <sup>-1</sup> (n = 15)	4 l.kg <sup>-1</sup> .min <sup>-1</sup> (n = 15)	Mean difference (95% CI)	P-value
Change in NIRS during apnoea period, %.min <sup>-1</sup>				
primary analysis	0.27 (0.48)	0.51 (0.33)	-0.24 (-0.55 - 0.07)	0.12
with baseline values	0.34 (0.23)	0.45 (0.23)	-0.11 (-0.28 - 0.06)	0.19
with multiple imputations (n=16 and 18)	0.26 (0.49)	0.50 (0.36)	-0.23 (-0.52 - 0.06)	0.11
excluding possible spontaneous breathers (n=13 and 13)	0.25 (0.51)	0.51 (0.36)	-0.26 (-0.62 - 0.10)	0.15
Change in tcO <sub>2</sub> during apnoea period, kPa.min <sup>-1</sup>				
primary analysis	0.63 (0.91)	0.12 (1.01)	0.51 (-0.20 - 1.23)	0.15
with baseline values	0.50 (0.86)	0.25 (0.86)	0.24 (-0.41 - 0.90)	0.45
with multiple imputations (n=16 and 18)	0.66 (0.95)	0.23 (1.14)	0.43 (-0.31 - 1.16)	0.24
excluding possible spontaneous breathers (both n=13)	0.49 (0.73)	0.09 (1.08)	0.40 (-0.35 - 1.14)	0.28

## Appendix

### Supplementary Table S1

Primary and sensitivity analyses of the primary outcome – change in transcutaneous CO<sub>2</sub> (tcCO<sub>2</sub> in kPa). The p-value for non-inferiority was calculated using the pre-defined non-inferiority of 0.147 kPa.min<sup>-1</sup>. Values for each group are given as mean (SD). The mean difference between groups is presented with a 95% confidence interval (CI).

	2 l.kg <sup>-1</sup> .min <sup>-1</sup> (n = 15)	4 l.kg <sup>-1</sup> .min <sup>-1</sup> (n = 15)	Mean difference (95% CI)	Upper limit of one-sided 95% CI	P-value for non-inferiority
Change in tcCO <sub>2</sub> during apnoea period, kPa.min <sup>-1</sup>					
primary analysis	0.46 (0.11)	0.46 (0.12)	-0.01 (-0.09 - 0.08)	0.07	<0.001
with baseline values	0.46 (0.12)	0.46 (0.12)	-0.00 (-0.09 - 0.08)	0.07	<0.001
with multiple imputations (n=16 and 18)	0.45 (0.12)	0.45 (0.13)	0.00 (-0.08 - 0.09)	0.07	<0.001
excluding possible spontaneous breathers (both n=13)	0.48 (0.10)	0.47 (0.11)	0.01 (-0.08 - 0.09)	0.08	0.001

**Supplementary Table S2**


Sensitivity analysis of the primary outcome – change in transcutaneous CO<sub>2</sub> (tcCO<sub>2</sub> in kPa) – using repeated measures over time. The p-value for non-inferiority was calculated using the pre-defined non-inferiority of 0.147 kPa.min<sup>-1</sup>. a: number of measurements. Values for each group are given as mean with 95% confidence interval (CI).

	2 l.kg <sup>-1</sup> .min <sup>-1</sup> (n=15, a=8271)	4 l.kg <sup>-1</sup> .min <sup>-1</sup> (n=15, a=8730)	Mean difference (95% CI)	Upper limit of one-sided 95% CI	P-value for non- inferiority
Change in tcCO <sub>2</sub> during apnoea period, kPa.min <sup>-1</sup>	0.51 (0.44 - 0.57)	0.51 (0.45 - 0.58)	-0.01 (-0.10 - 0.09)	0.07	0.001
Change in tcCO <sub>2</sub> during apnoea period without first 5 min, kPa.min <sup>-1</sup>	0.47 (0.38 - 0.55)	0.48 (0.40 - 0.57)	-0.02 (-0.14 - 0.10)	0.08	0.005



### Supplementary Figure S3

Measurements of transcutaneous CO<sub>2</sub> (tcCO<sub>2</sub> in kPa) over time for each patient for flows (A) 2 l.kg<sup>-1</sup>.min<sup>-1</sup> and (B) 4 l.kg<sup>-1</sup>.min<sup>-1</sup>. Patients indicated in red were suspected breathing spontaneously.



## References

1. Mayfield S, Jauncey-Cooke J, Hough JL, Schibler A, Gibbons K, Bogossian F. High-flow nasal cannula therapy for respiratory support in children. *Cochrane Database of Systematic Reviews* 2014: CD009850.
2. Sztrymf B, Messika J, Mayot T, Lenglet H, Dreyfuss D, Ricard JD. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study. *Journal of Critical Care* 2012; **27**: 324.e9-13.
3. Manley BJ, Owen LS, Doyle LW, et al. High-flow nasal cannulae in very preterm infants after extubation. *New England Journal of Medicine* 2013; **369**: 1425-33.
4. Schibler A, Pham TM, Dunster KR, et al. Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. *Intensive Care Medicine* 2011; **37**: 847-52.
5. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *New England Journal of Medicine* 2015; **372**: 2185-96.
6. Miguel-Montanes R, Hajage D, Messika J, et al. Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild-to-moderate hypoxemia. *Critical Care Medicine* 2015; **43**: 574-83.
7. Mir F, Patel A, Iqbal R, Cecconi M, Nouraei SA. A randomised controlled trial comparing transnasal humidified rapid insufflation ventilatory exchange (THRIVE) pre-oxygenation with facemask pre-oxygenation in patients undergoing rapid sequence induction of anaesthesia. *Anaesthesia* 2017; **72**: 439-43.
8. Lodenius A, Piehl J, Ostlund A, Ullman J, Jonsson Fagerlund M. Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) vs. facemask breathing pre-oxygenation for rapid sequence induction in adults: a prospective randomised non-blinded clinical trial. *Anaesthesia* 2018; **73**: 564-71.
9. Badiger S, John M, Fearnley RA, Ahmad I. Optimizing oxygenation and intubation conditions during awake fibre-optic intubation using a high-flow nasal oxygen-delivery system. *British Journal of Anaesthesia* 2015; **115**: 629-32.
10. Wong DT, Dallaire A, Singh KP, et al. High-Flow Nasal Oxygen Improves Safe Apnea Time in Morbidly Obese Patients Undergoing General Anesthesia: A Randomized Controlled Trial. *Anesthesia and Analgesia* 2019; **129**: 1130-6.
11. Waters E, Kellner M, Milligan P, Adamson RM, Nixon IJ, McNarry AF. The use of Transnasal Humidified Rapid-insufflation Ventilatory Exchange (THRIVE) in one hundred and five upper airway endoscopies. A case series. *Clinical Otolaryngology* 2019.
12. Riva T, Theiler L, Jaquet Y, Giger R, Nisa L. Early experience with high-flow nasal oxygen therapy (HFNOT) in pediatric endoscopic airway surgery. *International Journal of Pediatric Otorhinolaryngology* 2018; **108**: 151-4.
13. Humphreys S, Rosen D, Housden T, Taylor J, Schibler A. Nasal high-flow oxygen delivery in children with abnormal airways. *Paediatric Anaesthesia* 2017; **27**: 616-20.
14. Riva T, Seiler S, Stucki F, Greif R, Theiler L. High-flow nasal cannula therapy and apnea time in laryngeal surgery. *Paediatric Anaesthesia* 2016; **26**: 1206-08.
15. Riva T, Pedersen TH, Seiler S, et al. Transnasal humidified rapid insufflation ventilatory exchange for oxygenation of children during apnoea: a prospective randomized controlled trial. *British Journal of Anaesthesia* 2018; **120**: 592-99.
16. Patel A, Nouraei SA. Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE): a physiological method of increasing apnoea time in patients with difficult airways. *Anaesthesia* 2015; **70**: 323-9.

17. Humphreys S, Lee-Archer P, Reyne G, Long D, Williams T, Schibler A. Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) in children: a randomized controlled trial. *British Journal of Anaesthesia* 2017; **118**: 232-8.
18. Gustafsson IM, Lodenius A, Tunelli J, Ullman J, Jonsson Fagerlund M. Apnoeic oxygenation in adults under general anaesthesia using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) - a physiological study. *British Journal of Anaesthesia* 2017; **118**: 610-7.
19. Laviola M, Das A, Chikhani M, Bates DG, Hardman JG. Computer simulation clarifies mechanisms of carbon dioxide clearance during apnoea. *British Journal of Anaesthesia* 2019; **122**: 395-401.
20. Hermez LA, Spence CJ, Payton MJ, Nouraei SAR, Patel A, Barnes TH. A physiological study to determine the mechanism of carbon dioxide clearance during apnoea when using transnasal humidified rapid insufflation ventilatory exchange (THRIVE). *Anaesthesia* 2019; **74**: 441-9.
21. Frumin MJ, Epstein RM, Cohen G. Apneic oxygenation in man. *Anesthesiology* 1959; **20**: 789-98.
22. Eger EI, Severinghaus JW. The rate of rise of PaCO<sub>2</sub> in the apneic anesthetized patient. *Anesthesiology* 1961; **22**: 419-25.
23. Else SDN, Kovatsis PG. A Narrative Review of Oxygenation During Pediatric Intubation and Airway Procedures. *Anesthesia and Analgesia* 2020; **130**: 831-40.
24. Lyons C, Callaghan M. Apnoeic oxygenation in paediatric anaesthesia: a narrative review. *Anaesthesia* 2020.
25. Fraioli RL, Sheffer A, Steffenson JL. Pulmonary and cardiovascular effects of apneic oxygenation in man. *Anesthesiology* 1973; **39**: 588-96.
26. Lyons C, Callaghan M. Apnoeic oxygenation with high-flow nasal oxygen for laryngeal surgery: a case series. *Anaesthesia* 2017; **72**: 1379-87.
27. Bartlett RG, Jr., Brubach HF, Specht H. Demonstration of ventilatory mass flow during ventilation and apnea in man. *Journal of Applied Physiology* 1959; **14**: 97-101.
28. Riva T, Meyer J, Theiler L, et al. Measurement of airway pressure during high-flow nasal therapy in apnoeic oxygenation: a randomised controlled crossover trial. *Anaesthesia* 2020.
29. West JB, Hugh-Jones P. Pulsatile gas flow in bronchi caused by the heart beat. *Journal of Applied Physiology* 1961; **16**: 697-702.
30. Slutsky AS, Brown R. Cardiogenic oscillations - A potential mechanism enhancing oxygenation during apneic respiration. *Medical Hypotheses* 1982; **8**: 393-400.
31. Omori C, Schofield B, Mitzner W, Freed AN. Hyperpnea with dry air causes time-dependent alterations in mucosal morphology and bronchovascular permeability. *Journal of Applied Physiology* 1985; **78**: 1043-51.
32. Williams R, Rankin N, Smith T, Galler D, Seakins P. Relationship between the humidity and temperature of inspired gas and the function of the airway mucosa. *Critical Care Medicine* 1996; **24**: 1920-9.
33. Imray CH, Brearey S, Clarke T, et al. Cerebral oxygenation at high altitude and the response to carbon dioxide, hyperventilation and oxygen. The Birmingham Medical Research Expeditionary Society. *Clinical Science (London)* 2002; **98**: 159-64.